Oxypertine
|
WikiDoc Resources for Oxypertine |
|
Articles |
|---|
|
Most recent articles on Oxypertine |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Oxypertine at Clinical Trials.gov Clinical Trials on Oxypertine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Oxypertine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Oxypertine Discussion groups on Oxypertine Patient Handouts on Oxypertine Directions to Hospitals Treating Oxypertine Risk calculators and risk factors for Oxypertine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Oxypertine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Oxypertine (Equipertine, Forit, Integrin, Lanturil, Lotawin, Opertil) is an antipsychotic used in the treatment of schizophrenia.[1] Chemically, it is an indole derivative similarly to molindone and a member of the phenylpiperazine class.[2] Like reserpine and tetrabenazine, oxypertine depletes catecholamines, though not serotonin, possibly underlying its neuroleptic efficacy.[3]
See also
References
- ↑ Hall, Chapman and; Rhodes, P. H (1996). Dictionary of organic compounds. London: Chapman & Hall. ISBN 0-412-54090-8.
- ↑ Breulet M, Labar P, Delree C, Collard J, Bobon J (February 1968). "[Oxypertine, peperazine derivative of tryptophan with neuroleptic and dynamogenic properties]". Acta Neurol Psychiatr Belg (in French). 68 (2): 116–27. PMID 4972600.
- ↑ Bak IJ, Hassler R, Kim JS (1969). "Differential monoamine depletion by oxypertine in nerve terminals. Granulated synaptic vesicles in relation to depletion of norepinephrine, dopamine and serotonin". Zeitschrift Für Zellforschung Und Mikroskopische Anatomie (Vienna, Austria : 1948). 101 (3): 448–62. PMID 5362847.